Literature DB >> 29026966

The Clinical Implications of Liver Resection Margin Size in Patients with Hepatocellular Carcinoma in Terms of Positron Emission Tomography Positivity.

Jae Hyun Park1, Dong Hwi Kim1, Sung Hoon Kim2, Moon Young Kim3, Soon Koo Baik3, In Su Hong4.   

Abstract

BACKGROUND: The positivity of positron emission tomography (PET) in hepatocellular carcinoma (HCC) correlates with aggressive tumor factors and poor survival. Adequate resection margin size is still a topic of debate. We analyzed the clinical implications of resection margin size in patients with HCC in terms of PET positivity.
METHODS: We retrospectively reviewed the medical records of 92 patients who underwent liver resection from March 2012 to October 2015. We investigated prognostic factors for recurrence and survival. We analyzed the correlation of resection margin size and PET positivity. Resection margins were classified as less than 1 cm and more than 1 cm.
RESULTS: Twenty six (31.3%) patients had PET-positive HCC. Multivariate analysis showed PET, satellite nodules, microvessel invasion, and multicentric occurrence were significant prognostic factors for HCC recurrence. Multivariate analysis also showed satellite nodules and microscopic portal vein invasion were significant prognostic factors for overall survival (OS). Resection margin size did not affect disease-free survival (DFS) (p = 0.681) or OS (p = 0.301) in patients with PET-negative HCC, but showed a difference in DFS [<1 cm at 11 months vs. ≥1 cm at 41 months (p = 0.188)] and OS [<1 cm at 28 months vs. ≥1 cm at 48 months (p < 0.001)] in patients with PET-positive HCC.
CONCLUSIONS: PET has low sensitivity for HCC. However, it is useful to predict treatment outcomes after liver resection or liver transplantation for HCC. Although the extent of liver resection must be decided based on liver function, a resection margin size >1 cm may improve DFS and OS in patients with PET-positive HCC.

Entities:  

Mesh:

Year:  2018        PMID: 29026966     DOI: 10.1007/s00268-017-4275-1

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  27 in total

1.  Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver.

Authors:  J Bruix; M Sherman; J M Llovet; M Beaugrand; R Lencioni; A K Burroughs; E Christensen; L Pagliaro; M Colombo; J Rodés
Journal:  J Hepatol       Date:  2001-09       Impact factor: 25.083

Review 2.  [18F]fludeoxyglucose positron emission tomography and computed tomography as a prognostic tool before liver transplantation, resection, and loco-ablative therapies for hepatocellular carcinoma.

Authors:  Yael Asman; Amy R Evenson; Einat Even-Sapir; Oren Shibolet
Journal:  Liver Transpl       Date:  2015-04-01       Impact factor: 5.799

3.  Evidence-based Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2013 update (3rd JSH-HCC Guidelines).

Authors:  Norihiro Kokudo; Kiyoshi Hasegawa; Masaaki Akahane; Hiroshi Igaki; Namiki Izumi; Takafumi Ichida; Shinji Uemoto; Shuichi Kaneko; Seiji Kawasaki; Yonson Ku; Masatoshi Kudo; Shoji Kubo; Tadatoshi Takayama; Ryosuke Tateishi; Takashi Fukuda; Osamu Matsui; Yutaka Matsuyama; Takamichi Murakami; Shigeki Arii; Masatoshi Okazaki; Masatoshi Makuuchi
Journal:  Hepatol Res       Date:  2015-01       Impact factor: 4.288

Review 4.  A systematic review of microvascular invasion in hepatocellular carcinoma: diagnostic and prognostic variability.

Authors:  Manuel Rodríguez-Perálvarez; Tu Vinh Luong; Lorenzo Andreana; Tim Meyer; Amar Paul Dhillon; Andrew Kenneth Burroughs
Journal:  Ann Surg Oncol       Date:  2012-11-13       Impact factor: 5.344

Review 5.  Is resection or transplantation the ideal treatment in patients with hepatocellular carcinoma in cirrhosis if both are possible? A systematic review and metaanalysis.

Authors:  Andrea Proneth; Florian Zeman; Hans J Schlitt; Andreas A Schnitzbauer
Journal:  Ann Surg Oncol       Date:  2014-05-28       Impact factor: 5.344

Review 6.  Oncologic resection for malignant tumors of the liver.

Authors:  Shefali Agrawal; Jacques Belghiti
Journal:  Ann Surg       Date:  2011-04       Impact factor: 12.969

Review 7.  Hepatocellular carcinoma.

Authors:  Alejandro Forner; Josep M Llovet; Jordi Bruix
Journal:  Lancet       Date:  2012-02-20       Impact factor: 79.321

8.  Salvage Versus Primary Liver Transplantation for Early Hepatocellular Carcinoma: Do Both Strategies Yield Similar Outcomes?

Authors:  Prashant Bhangui; Marc Antoine Allard; Eric Vibert; Daniel Cherqui; Gilles Pelletier; Antonio Sa Cunha; Catherine Guettier; Jean-Charles Duclos Vallee; Faouzi Saliba; Henri Bismuth; Didier Samuel; Denis Castaing; René Adam
Journal:  Ann Surg       Date:  2016-07       Impact factor: 12.969

9.  Comparison of the outcomes between an anatomical subsegmentectomy and a non-anatomical minor hepatectomy for single hepatocellular carcinomas based on a Japanese nationwide survey.

Authors:  Susumu Eguchi; Takashi Kanematsu; Shigeki Arii; Masatoshi Okazaki; Kiwamu Okita; Masao Omata; Iwao Ikai; Masatoshi Kudo; Masamichi Kojiro; Masatoshi Makuuchi; Morito Monden; Yutaka Matsuyama; Yasuni Nakanuma; Kenichi Takayasu
Journal:  Surgery       Date:  2008-04       Impact factor: 3.982

10.  Management of hepatocellular carcinoma: an update.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2011-03       Impact factor: 17.425

View more
  6 in total

1.  Robotic liver resection for hepatocellular carcinoma: analysis of surgical margins and clinical outcomes from a western tertiary hepatobiliary center.

Authors:  Emanuel Shapera; Kaitlyn Crespo; Cameron Syblis; Sharona Ross; Alexander Rosemurgy; Iswanto Sucandy
Journal:  J Robot Surg       Date:  2022-10-21

Review 2.  Radiomics in hepatocellular carcinoma: a quantitative review.

Authors:  Taiga Wakabayashi; Farid Ouhmich; Cristians Gonzalez-Cabrera; Emanuele Felli; Antonio Saviano; Vincent Agnus; Peter Savadjiev; Thomas F Baumert; Patrick Pessaux; Jacques Marescaux; Benoit Gallix
Journal:  Hepatol Int       Date:  2019-08-31       Impact factor: 9.029

Review 3.  18F-fludeoxyglucose positron emission tomography for diagnosis of HCC: implications for therapeutic strategy in curative and non-curative approaches.

Authors:  Arno Kornberg; Helmut Friess
Journal:  Therap Adv Gastroenterol       Date:  2019-03-19       Impact factor: 4.802

4.  Impact of Surgical Margin on the Prognosis of Early Hepatocellular Carcinoma (≤5 cm): A Propensity Score Matching Analysis.

Authors:  Han Wang; Hua Yu; You-Wen Qian; Zhen-Ying Cao; Meng-Chao Wu; Wen-Ming Cong
Journal:  Front Med (Lausanne)       Date:  2020-05-07

5.  Prognostic value of 18F-fluorodeoxyglucose positron emission tomography in patients with small hepatocellular carcinoma treated by radiofrequency ablation.

Authors:  Yoshiyuki Ida; Hideyuki Tamai; Naoki Shingaki; Ryo Shimizu; Shuya Maeshima; Takao Maekita; Mikitaka Iguchi; Masaki Terada; Masayuki Kitano
Journal:  Cancer Imaging       Date:  2020-10-19       Impact factor: 3.909

6.  Prognostic Impact of Surgical Margin in Hepatectomy on Patients With Hepatocellular Carcinoma: A Meta-Analysis of Observational Studies.

Authors:  Yeting Lin; Jiaxuan Xu; Jiaze Hong; Yuexiu Si; Yujing He; Jinhang Zhang
Journal:  Front Surg       Date:  2022-02-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.